The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes ; volume:11 ; number:4 ; day:17 ; month:3 ; year:2020 ; pages:835-844 ; date:4.2020
Diabetes therapy ; 11, Heft 4 (17.3.2020), 835-844, 4.2020
- Urheber
-
Yin, Win L.
Bain, Steve C.
Min, Thinzar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-020-00798-x
- URN
-
urn:nbn:de:101:1-2020062222571948743632
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yin, Win L.
- Bain, Steve C.
- Min, Thinzar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Glucagon-like peptide 1 (GLP-1)
Glucagon-like peptide-1 7-36 amid
The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence
Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features